Scholarlink

<p>Chikungunya is an acute illness caused by the chikungunya virus (CHIKV) and spread by Aedes mosquitoes. It has now been reported in over 100 countries, posing an increasing public health challenge. The disease presents with a range of symptoms, most commonly fever, rash, and joint pain. There are still no specific antiviral drugs available, and treatment remains largely supportive. Vaccine development has made some headway, but challenges around safety, immune response, and real-world use persist. This article reviews what is known about the epidemiology, pathogenesis, clinical features, treatment options, and vaccine progress for chikungunya. It also looks at the key bottlenecks that continue to hinder translation from basic research to clinical practice, and argues that new technology platforms and stronger international collaboration are needed to advance the development of targeted drugs and safe, effective vaccines—so that we can better tackle this global health threat.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From symptom management to immune prevention: a comprehensive review of chikungunya treatment and vaccine development

  • 期刊论文

  • 发表日期：

    2026年7月10日

查看全文
  • Xin Li,
  • Zijun Yuan,
  • Junjie Ni,
  • Dinglei Rao,
  • Wenxian Yin,
  • Xu Wu,
  • Mingxing Li,
  • Fukuan Du,
  • Yueshui Zhao,
  • Jing Shen,
  • Xi He,
  • Chi Hin Cho,
  • Zhangang Xiao

摘要

Chikungunya is an acute illness caused by the chikungunya virus (CHIKV) and spread by Aedes mosquitoes. It has now been reported in over 100 countries, posing an increasing public health challenge. The disease presents with a range of symptoms, most commonly fever, rash, and joint pain. There are still no specific antiviral drugs available, and treatment remains largely supportive. Vaccine development has made some headway, but challenges around safety, immune response, and real-world use persist. This article reviews what is known about the epidemiology, pathogenesis, clinical features, treatment options, and vaccine progress for chikungunya. It also looks at the key bottlenecks that continue to hinder translation from basic research to clinical practice, and argues that new technology platforms and stronger international collaboration are needed to advance the development of targeted drugs and safe, effective vaccines—so that we can better tackle this global health threat.